The biological significance of estrogen receptor-negative but progesterone receptor-positive breast carcinomas is not clear. In the present study the aggressiveness of breast carcinomas in relation to ER and PgR status has been investigated. The probability of disease-free survival in 297 node-negative breast carcinoma patients was monitored during a follow-up ranging from six to 96 months (median 45 months). Steroid hormone receptor content was assayed with the biochemical method recommended by the EORTC. The probability of disease-free survival was significantly worse for patients with ER-negative, PgR-positive carcinomas compared to the other three steroid hormone receptor phenotypes. Our results suggest that ER-negative, PgR-positive breast carcinomas are biologically different in terms of aggressiveness from the other steroid hormone receptor phenotypes.
ThorpeS.M.Estrogen and progesterone receptor determination in breast cancer. Technology, biology and clinical significance. Acta Oncol1988; 27: 1–19.
2.
MuldoonT.G.Regulation of steroid hormone receptor activity. Endocrine Rev1980; 1: 339–64.
3.
HorowitzK.B., McGuireW.L., PearsonO.H., SegaloffA.Predicting response of endocrine therapy in human breast cancer. A hypothesis. Science1975; 189: 726–7.
American Joint Committee on Cancer:Manual for staging of cancer, 3rd ed.Philadelphia: JB Lippincott, 1987.
6.
ScarffR.F., TorloniH.Histological typing of breast tumors: International histological classification of tumors II.Geneva: World Health Organization1968; 19.
7.
BloomH.J.G., RichardsonW.W.Histological grading in breast cancer. Br J Cancer1957; 11: 359–77.
8.
EORTC Breast Cancer Cooperative Group:Revision of the standards for the assessment of receptors in human breast cancer. Eur J Cancer1980; 16: 1513–5.
9.
Nikolic-VukosavljevicD., Brankovic-MagicM., PolicD., VlajicM., VuleticL., SpuzicI.Estrogen dependence of primary breast cancer - correlation with histologic type and grade. Neoplasma1992; 39: 299–304.
10.
Nikolic-VukosavljevicD., Brankovic-MagicM., PolicD., JankovicR.Standardization of steroid hormone receptor assay. Yugoslav Med Biochem1998; 17: 391–4.
11.
RomainS., Laine BidronC., MartinP.M., MagdelénatH.Steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. The EORTC Receptor Study Group. Eur J Cancer1995, 31A: 411–7.
12.
FisherB., RedmondC., FisherE.R., CaplanR.Relative worth of estrogen and progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol1988; 7: 1076–87.
13.
MathiesenO., BonderupX., CarlJ., PanduroJ., PedersenK.O.The prognostic value of estrogen and progesterone receptors in female breast cancer. A single center study. Acta Oncol1991; 30: 691–5.
14.
ChevallierB., MosseriV., DauceJ.P., BastitP., JulienJ.P., AsselainB.A prognostic score in histological node negative breast cancer. Br J Cancer1990; 61: 436–40.
15.
WittliffJ.L.Steroid-hormone receptors in breast cancer. Cancer1984; 53: 630–43.
16.
MireckiD.M., JordanV.C.Steroid hormone receptors and human breast cancer. Lab Med1985; 16: 287–94.
17.
MuresanZ., DutuR., VoiculetzN.Relationships of steroid hormone receptors, age, and histological characteristics in human breast cancer. Neoplasma1986; 33: 371–7.
18.
WilkingN., RutquistL.E., NordenskjoldB., SkoogL.Steroid receptor levels in breast cancer. Relationships with age and menopausal status. Acta Oncol1989; 28: 807–10.
19.
Anonymous.Breast cancer estrogen and progesterone receptors: Associations with patients’ clinical and epidemiolgic characteristics. GIVIO (Interdisciplinary Group for Cancer Care Evaluation), Italy. Tumori1991; 77: 472–8.
20.
Nikolic-VukosavljevicD., VasiljevicN., Brankovic-MagicM., PolicD.J.Variations in steroid hormone receptor content throughout age and menopausal periods, and menstrual cycle in breast cancer patients. Neoplasma1996; 43: 163–9.
21.
ClarkeR., LippmanM.E.Antiestrogen resistance: mechanisms and reversal. In: TeicherB.A., ed. Drug resistance in oncology.New York: Marcel Dekker Inc., 1992; 501–36.
22.
McGuireW.L., OsborneC.K., ClarkG.M., KnightW.A.Steroid hormone receptors and carcinoma of the breast. Am J Physiol1982; 243: 99–102.
23.
StewartH.J., PrescottR.Adjuvant tamoxifen therapy of dependence of receptor level (letter). Lancet1985; 1: 573.
